Tranexamic Acid vs. Quixil - Reducing Blood Loss in Joint Replacement

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

We will compare the effectiveness of Quixil and Tranexamic acid in reducing bleeding during hip and knee joint replacements.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Golden Jubilee National Hospital
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Patients who are to undergo elective hip or knee joint replacement

• Must be cemented arthroplasty

• Must be primary arthroplasty

Exclusion Criteria:

• Uncemented arthroplasty.

• Revision arthroplasty.

• Patients on anticoagulant (warfarin, low molecular weight heparin) or other medication known to affect clotting (except aspirin, which is to be given as part of standard DVT prophylaxis in all cases).

• Other drugs that may affect the activity of the drugs under investigation.

• Allergy to asprin (all patients to receive 150mg aspirin as standard DVT prophylaxis for 6 weeks).

• Patients with known coagulopathy (APTT or PT outside normal range pre-operatively).

• Previous reaction or ethical/religious objection to receiving blood products (Quixil contains a derivative of human blood).

• Pregnancy or breastfeeding.

• Patients who have a past medical history of thrombo-embolism at any time.

• Patients who need intravenous fluid administration for greater than 24 hours following operation.

• Patients who need allogenic blood transfusion within study period.

• Jehovah's Witnesses, or any other group of patients with ethical objections to receiving blood products.